FDA Approves Moderna’s mRNA Flu Vaccine; Phase IV Now Determines Senior Evidence

The FDA approved Moderna’s mFlusiva on August 6, 2026, making it the first mRNA-based influenza vaccine authorized in the United States. The agency granted traditional approval for adults aged 50 to 64 but used accelerated approval for those 65 and